dc.contributor.author | Tolu, Sena | |
dc.contributor.author | Rezvani, Aylin | |
dc.contributor.author | Hindioğlu, Nurbanu | |
dc.contributor.author | Çalkın Korkmaz, Merve | |
dc.date.accessioned | 10.07.201910:49:13 | |
dc.date.accessioned | 2019-07-10T19:50:03Z | |
dc.date.available | 10.07.201910:49:13 | |
dc.date.available | 2019-07-10T19:50:03Z | |
dc.date.issued | 2018 | en_US |
dc.identifier.citation | Tolu, S., Rezvani, A., Hindioğlu, N. ve Korkmaz, M. (2018). Etanercept-induced Crohn's disease in ankylosing spondylitis: A case report and review of the literature. Rheumatology International, 38(11), 2157-2162. https://dx.doi.org/10.1007/s00296-018-4165-3 | en_US |
dc.identifier.issn | 0172-8172 | |
dc.identifier.issn | 1437-160X | |
dc.identifier.uri | https://dx.doi.org/10.1007/s00296-018-4165-3 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/1866 | |
dc.description | WOS: 000448513400023 | en_US |
dc.description | PubMed ID: 30293157 | en_US |
dc.description.abstract | Tumor necrosis factor (TNF)- is a cytokine that plays a well-established, key role as a central mediator of inflammation and immune regulation. TNF- and its receptors are suggested to play a critical role in a number of chronic inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (AS), juvenile chronic arthritis, and inflammatory bowel disease (IBD). TNF- inhibitors are currently used in the treatment of these diseases. We report a 29-year-old male with AS who developed Crohn's disease while taking etanercept. Etanercept treatment was interrupted and a switch to a monoclonal antibody-based anti-TNF treatment using adalimumab was started, which induced a prompt improvement of the gastrointestinal symptoms. We indicate the immunodysregulatory and proinflammatory effects of etanercept and discuss the potential pathogenic mechanisms of the paradoxical effect of TNF- inhibitors. We also review the related literature on new-onset IBD following anti-TNF treatment for AS. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer Heidelberg | en_US |
dc.rights | info:eu-repo/semantics/embargoedAccess | en_US |
dc.subject | Ankylosing Spondylitis | en_US |
dc.subject | Crohn's Disease | en_US |
dc.subject | Tumor Necrosis Factor Alpha Inhibitors | en_US |
dc.subject | Etanercept | en_US |
dc.subject | Mechanism of Action | en_US |
dc.title | Etanercept-induced Crohn's disease in ankylosing spondylitis: A case report and review of the literature | en_US |
dc.type | review | en_US |
dc.relation.ispartof | Rheumatology International | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Fizik Tedavi ve Rehabilitasyon Ana Bilim Dalı | en_US |
dc.authorid | 0000-0002-1111-3110 | en_US |
dc.authorid | 0000-0002-5852-3854 | en_US |
dc.authorid | 0000-0002-0756-2351 | en_US |
dc.identifier.volume | 38 | en_US |
dc.identifier.issue | 11 | en_US |
dc.identifier.startpage | 2157 | en_US |
dc.identifier.endpage | 2162 | en_US |
dc.relation.publicationcategory | Diğer | en_US |
dc.identifier.doi | 10.1007/s00296-018-4165-3 | en_US |
dc.identifier.wosquality | Q4 | en_US |
dc.identifier.scopusquality | Q2 | en_US |